DTaP-polio combo vaccine does well in Phase III trials

Article

Positive Phase III results from a vaccine that combines four existing immunizations together were reported online by Pediatric Infectious Disease Journal.

Positive Phase III results from a vaccine that combines four existing immunizations together were reported online by Pediatric Infectious Disease Journal.

Kinrix is GlaxoSmithKline's name for a combination of inactivated polio and a DTaP (diphtheria, tetanus, and acellular pertussis) vaccinations. The combined product would require one shot, not two.

The phase III results showed immune response and safety profile to the individually-administered shots. It enrolled over 4,000 children ages 4 to 6. The most common adverse event was injection site pain (over 50%, followed by redness, swelling, and increase in arm circumference (all over 25%).

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
David Brousseau, MD, highlights impact of timely opioid dosing in pediatric sickle cell pain
August's FDA Focus: Approvals and pipeline updates in pediatrics | Image credit: Contemporary Pediatrics
© 2025 MJH Life Sciences

All rights reserved.